Health care-related economic burden of the polycystic ovary syndrome during the reproductive life Span

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 8, 2005, Pages 4650-4658

  Azziz, Ricardo ^a,b   Marin, Catherine ^a,b   Hoq, Lalima ^c   Badamgarav, Enkhe ^c   Song, Paul ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Cerner Health Insights   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE CITRATE; HORMONE; METFORMIN; ORAL CONTRACEPTIVE AGENT; SPIRONOLACTONE; TROGLITAZONE;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DRUG COST; FERTILIZATION IN VITRO; HEALTH CARE COST; HIRSUTISM; HUMAN; INCIDENCE; INFERTILITY; LIFESPAN; MEDICAL ASSESSMENT; MENSTRUATION DISORDER; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; REPRODUCTION; REVIEW; SYSTEMATIC REVIEW; UTERUS BLEEDING;

ADOLESCENT; ADULT; FEMALE; HEALTH CARE COSTS; HUMANS; INCIDENCE; POLYCYSTIC OVARY SYNDROME; PREVALENCE; UNITED STATES;

EID: 23844453653     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2005-0628     Document Type: Review

References (98)

1. Stein IF, Leventhal NL 1935 Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29:181-191
2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO 2004 The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745-2749
3. Hull MG 1981 Ovulation failure and induction. Clin Obstet Gynaecol 8:753-785
4. Legro RS 2000 The genetics of obesity. Lessons for polycystic ovary syndrome. Ann NY Acad Sci 900:193-202
5. Ovalle F, Azziz R 2002 Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 77:1095-1105
6. Nestler JE 1997 Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin Reprod Endocrinol 15:111-122
7. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG 1991 A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72:83-89
8. Plymate SR, Jones RE, Matej LA, Friedl KE 1988 Regulation of sex hormone binding globulin (SHBG) production in Hep G2 cells by insulin. Steroids 52:339-340
9. Plymate SR, Matej LA, Jones RE, Friedl KE 1988 Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 67:460-464
10. Wild S, Pierpoint T, McKeigue P, Jacobs H 2000 Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 52:595-600
11. Legro RS 2003 Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 24:302-312
12. Bjercke S, Dale PO, Tanbo T, Storeng R, Ertzeid G, Abyholm T 2002 Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecol Obstet Invest 54:94-98
13. Michelmore KF, Balen AH, Dunger DB, Vessey MP 1999 Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 51:779-786
14. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI 1999 A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84:4006-4011
15. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF 2000 A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85:2434-2438
16. Population Reference Bureau 2002 World population data sheet of the population reference bureau: demographic data and estimates for the countries and regions of the world. Washington, DC: Population Reference Bureau
17. Zawadzki JK, Dunaif A 1992 Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Boston: Blackwell Scientific Publications; 377-384
18. 2004 Drug topics red book. 108th ed. Stamford, CT: Thomson Healthcare
19. Centers for Medicare and Medicaid Services 2004 Centers for Medicare and Medicaid Services (CMS) physician fee schedules. Available at: http://www.cms.hhs.gov/physicians/mpfsapp/display.asp
20. Centers for Medicare and Medicaid Services 2005 Clinical laboratory fee schedules. Baltimore, MD: Centers for Medicare and Medicaid Services
21. U.S. Department of Labor 2005 Consumer price index: all urban consumers (Medical Care Services). Washington DC: Bureau of Labor Statistics, Division of Consumer Prices and Price Indexes
22. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R 1998 Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83:3078-3082
23. U.S. Census Bureau Census 2000 Summary file 1, QT-P3. Washington DC: U.S. Census Bureau, Population Division
24. Azziz R, Waggoner WT, Ochoa T, Knochenhauer ES, Boots LR 1998 Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama. Fertil Steril 70:274-278
25. Carmina E 1998 Prevalence of idiopathic hirsutism. Eur J Endocrinol 139:421-423
26. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR 2004 Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 89:453-462
27. Goldzieher JW, Axelrod LR 1963 Clinical and biochemical features of polycystic ovarian disease. Fertil Steril 14:631-653
28. Conway GS, Honour JW, Jacobs HS 1989 Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol (Oxf) 30:459-470
29. Cheung AP 2001 Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol 98:325-331
30. Chamlian DL, Taylor HB 1970 Endometrial hyperplasia in young women. Obstet Gynecol 36:659-666
31. Balen A 2001 Polycystic ovary syndrome and cancer. Hum Reprod Update 7:522-525
32. Hardiman P, Pillay OC, Atiomo W 2003 Polycystic ovary syndrome and endometrial carcinoma. Lancet 361:1810-1812
33. Dockerty MB, Jackson RL 1957 The Stein-Leventhal syndrome: analysis of 43 cases with special reference to association with endometrial carcinoma. Am J Obstet Gynecol 73:161-173
34. Critchley HO, Warner P, Lee AJ, Brechin S, Guise J, Graham B 2004 Evaluation of abnormal uterine bleeding: comparison of three outpatient procedures within cohorts defined by age and menopausal status. Health Technol Assess 8:iii-iv, 1-139
35. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN 2001 Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86:1626-1632
36. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, Jacobs HS 1995 Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 10:2107-2111
37. Goldzieher JW 1981 Polycystic ovarian disease. Fertil Steril 35:371-394
38. Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ, Ehrmann DA 2002 Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPAR γgene. J Clin Endocrinol Metab 87:772-775
39. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J 1999 Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22:141-146
40. Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN 2005 Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:66-71
41. Solomon CG, Hu FB, Dunaif A, Rich-Edwards J, Willett WC, Hunter DJ, Colditz GA, Speizer FE, Manson JE 2001 Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 286:2421-2426
42. Harris MI, Hadden WC, Knowler WC, Bennett PH 1987 Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 36:523-534
43. Schiller JS, Coriaty Nelson Z, Hao C, Barnes P 2004 Early release of selected estimates based on data from the January-March 2004 National Health Interview Survey. National Center for Health Statistics. March, 2005
44. Williamson K, Gunn AJ, Johnson N, Milsom SR 2001 The impact of ethnicity on the presentation of polycystic ovarian syndrome. Aust N Z J Obstet Gynaecol 41:202-206
45. Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA 1992 Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 167:1807-1812
46. Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE 2002 Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf) 57:343-350
47. Azziz R 2000 The time has come to simplify the evaluation of the hirsute patient. Fertil Steril 74:870-872
48. Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19-25
49. Azziz R, Hincapie LA, Knochenhauer ES, Dewailly D, Fox L, Boots LR 1999 Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril 72:915-925
50. Braunstein JB, Hausfeld J, Hausfeld J, London A 2003 Economics of reducing menstruation with trimonthly cycle oral contraceptive therapy: comparison with standard-cycle regimens. Obstet Gynecol 102:699-708
51. Katz P, Nachtigall R, Showstack J 2002 The economic impact of the assisted reproductive technologies. Nat Med 8(Suppl):S29-S32
52. Karande VC, Korn A, Morris R, Rao R, Balin M, Rinehart J, Dohn K, Gleicher N 1999 Prospective randomized trial comparing the outcome and cost of in vitro fertilization with that of a traditional treatment algorithm as first-line therapy for couples with infertility. Fertil Steril 71:468-475
53. Blackwell RE, Hammond KR, Steinkampf MP 2001 A one-year experience with a capitated health care plan for infertility. Fertil Steril 75:749-753
54. Hogan P, Dall T, Nikolov P 2003 Economic costs of diabetes in the U.S. in 2002. Diabetes Care 26:917-932
55. Moran C, Azziz R, Carmina E, Dewailly D, Fruzzetti F, Ibanez L, Knochenhauer ES, Marcondes JA, Mendonca BB, Pignatelli D, Pugeat M, Rohmer V, Speiser PW, Witchel SF 2000 21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. Am J Obstet Gynecol 183:1468-1474
56. Winters SJ, Talbott E, Guzick DS, Zborowski J, McHugh KP 2000 Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril 73:724-729
57. Piltonen T, Koivunen R, Perheentupa A, Morin-Papunen L, Ruokonen A, Tapanainen JS 2004 Ovarian age-related responsiveness to human chorionic gonadotropin in women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:3769-3775
58. Kim WR 2002 The burden of hepatitis C in the United States. Hepatology 36:S30-S34
59. Arterburn DE, Maciejewski ML, Tsevat J 2005 Impact of morbid obesity on medical expenditures in adults. Int J Obes Relat Metab Disord 29:334-339
60. Cote I, Jacobs P, Cumming D 2002 Work loss associated with increased menstrual loss in the United States. Obstet Gynecol 100:683-687
61. Ciampelli M, Fulghesu AM, Lanzone A 1999 Comment on "Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome." J Clin Endocrinol Metab 84:2974-2975
62. Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A 2001 Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 16:226-229
63. Wortsman J, de Angeles S, Futterweit W, Singh KB, Kaufmann RC 1991 Gestational diabetes and neonatal macrosomia in the polycystic ovary syndrome. J Reprod Med 36:659-661
64. Radon PA, McMahon MJ, Meyer WR 1999 Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstet Gynecol 94:194-197
65. Diamant YZ, Rimon E, Evron S 1982 High incidence of preeclamptic toxemia in patients with polycystic ovarian disease. Eur J Obstet Gynecol Reprod Biol 14:199-204
66. de Vries MJ, Dekker GA, Schoemaker J 1998 Higher risk of preeclampsia in the polycystic ovary syndrome. A case control study. Eur J Obstet Gynecol Reprod Biol 76:91-95
67. Fridstrom M, Nisell H, Sjoblom P, Hillensjo T 1999 Are women with polycystic ovary syndrome at an increased risk of pregnancy-induced hypertension and/or preeclampsia? Hypertens Pregnancy 18:73-80
68. Kashyap S, Claman P 2000 Polycystic ovary disease and the risk of pregnancy-induced hypertension. J Reprod Med 45:991-994
69. Glueck CJ, Bornovali S, Pranikoff J, Goldenberg N, Dharashivkar S, Wang P 2004 Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet Med 21:829-836
70. Sagle M, Bishop K, Ridley N, Alexander FM, Michel M, Bonney RC, Beard RW, Franks S 1988 Recurrent early miscarriage and polycystic ovaries. BMJ 297:1027-1028
71. Homburg R, Armar NA, Eshel A, Adams J, Jacobs HS 1988 Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ 297:1024-1026
72. Balen AH, Tan SL, MacDougall J, Jacobs HS 1993 Miscarriage rates following in vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum Reprod 8:959-964
73. Watson H, Kiddy DS, Hamilton-Fairley D, Scanlon MJ, Barnard C, Collins WP, Bonney RC, Franks S 1993 Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage. Hum Reprod 8:829-833
74. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE 2002 Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 87:524-529
75. Regan L, Owen EJ, Jacobs HS 1990 Hypersecretion of luteinising hormone, infertility, and miscarriage. Lancet 336:1141-1144
76. Legro RS, Kunselman AR, Dodson WC, Dunaif A 1999 Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165-169
77. Hernan WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE, Lachin JM, Engelgau MM 2003 Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 26:36-47
78. American Heart Association 2004 Heart disease and stroke statistics: 2004 update. Dallas: American Heart Association
79. Talbott EO, Zborowski JV, Sutton-Tyrrell K, McHugh-Pemu KP, Guzick DS 2001 Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am 28:111-133, vii
80. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A 1992 Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71:599-604
81. Sukalich S, Guzick D 2003 Cardiovascular health in women with polycystic ovary syndrome. Semin Reprod Med 21:309-315
82. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, Speizer FE, Manson JE 2002 Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 87:2013-2017
83. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS 2004 Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:5454-5461
84. Orio Jr F, Palomba S, Spinelli L, Cascella T, Tauchmanova L, Zullo F, Lombardi G, Colao A 2004 The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 89:3696-3701
85. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C 2004 Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 89:5592-5596
86. Elting MW, Korsen TJ, Bezemer PD, Schoemaker J 2001 Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 16:556-560
87. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS 1998 Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 51:581-586
88. Guyatt G, Weaver B, Cronin L, Dooley JA, Azziz R 2004 Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. J Clin Epidemiol 57:1279-1287
89. Sonino N, Fava GA, Mani E, Belluardo P, Boscaro M 1993 Quality of life of hirsute women. Postgrad Med J 69:186-189
90. Sanchez LA, Perez M, Azziz R 2002 Laser hair reduction in the hirsute patient: a critical assessment. Hum Reprod Update 8:169-181
91. Futterweit W, Dunaif A, Yeh HC, Kingsley P 1988 The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol 19:831-836
92. O'Driscoll JB, Mamtora H, Higginson J, Pollock A, Kane J, Anderson DC 1994 A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia. Clin Endocrinol (Oxf) 41:231-236
93. Cela E, Robertson C, Rush K, Kousta E, White DM, Wilson H, Lyons G, Kingsley P, McCarthy MI, Franks S 2003 Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol 149:439-442
94. Dawson KG, Gomes D, Gerstein H, Blanchard JF, Kahler KH 2002 The economic cost of diabetes in Canada, 1998. Diabetes Care 25:1303-1307
95. Leigh JP, McCurdy SA, Schenker MB 2001 Costs of occupational injuries in agriculture. Public Health Rep 116:235-248
96. Goodarzi MO, Quinones MJ, Yang H, Azziz R, Rotter JI, Hsueh WA, The prevalence of polycystic ovary syndrome in Mexican American women. Fertil Steril, in press
97. Dumesic DA, Herrmann RR, O'Brien AM 1997 Estimated prevalence of undiagnosed glucose intolerance from hyperandrogenic anovulation among women requesting electrolysis. Int J Fertil Womens Med 42:255-260
98. Farah L, Lazenby AJ, Boots LR, Azziz R 1999 Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists. Alabama Professional Electrology Association Study Group. J Reprod Med 44:870-874